$25.38 -0.27 (-1.05%)
11/27/2009 1:00 PM

Bristol-Myers Squibb Co. (BMY)

CAPS Rating: 5 out of 5

The Company, through its divisions and subsidiaries, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other health care related products.

Results 1 - 20 of 199 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar JamesMBaker (66.68) Submitted: 11/11/2009 9:07:43 AM : Outperform Start Price: $23.41 BMY Score: +9.09

Drugs will enhance our quality of life and they are just now getting started. BMY has a good portfolio and management is focused on enhancing revenues for future growth. Great dividend also. What's not to like?

Recs

0
Member Avatar SammyJ826 (93.77) Submitted: 11/3/2009 4:22:44 PM : Outperform Start Price: $21.99 BMY Score: +11.57

Strong dividend, strong earnings. This one adds some safety to my real life aggressive portfolio

Recs

0
Member Avatar jdcarcollector (21.86) Submitted: 11/3/2009 10:59:12 AM : Outperform Start Price: $21.82 BMY Score: +11.22

Fat yield.

Recs

0
Member Avatar Wendykitty (43.16) Submitted: 10/26/2009 9:35:17 PM : Outperform Start Price: $21.97 BMY Score: +13.15

BMY is a solid company with a great dividend. People will be looking for such a stable company to balance their portfolios. I don't think Obama's health care plan will hurt it either.

Recs

0
Member Avatar bigmike7 (72.57) Submitted: 10/23/2009 8:39:52 PM : Outperform Start Price: $22.26 BMY Score: +12.75



good time to buy - good dividend @ 5.5% - real potential for takeover in near furure-eh

Recs

0
Member Avatar acts412 (72.25) Submitted: 10/10/2009 11:21:41 PM : Outperform Start Price: $22.59 BMY Score: +9.97

positive independent ratings. best drug manufacturer. S&P 5 stars. 5.5% div. historically low PE of 13 x's trailing EPS.

Recs

0
Member Avatar rudcpr (56.56) Submitted: 10/10/2009 1:44:30 PM : Outperform Start Price: $22.85 BMY Score: +9.39

Abilify for adjunctive treatment of depression has been a huge success and patients are reporting results within 1-2 weeks which is unprecedented for an antidepressant (unless it's placebo effect). Analysts are aware of the potential here, but I think the next set of earnings will beat.

Recs

0
Member Avatar richardrogers4 (64.96) Submitted: 9/30/2009 3:19:33 AM : Outperform Start Price: $22.74 BMY Score: +8.59

Momentum / defensive pick

Recs

0
Member Avatar 30andholding (93.16) Submitted: 9/16/2009 2:27:46 PM : Outperform Start Price: $22.29 BMY Score: +11.09

P/E is not overly high. There's a good dividend and they have enough cash on hand to completely cover their LT debt.

Recs

0
Member Avatar liketechxyz (46.36) Submitted: 9/15/2009 10:22:33 AM : Outperform Start Price: $21.89 BMY Score: +11.30

Leading Pharma

Recs

0
Member Avatar Mliaom (21.87) Submitted: 9/13/2009 5:09:21 PM : Outperform Start Price: $22.01 BMY Score: +9.33

Quality Med Related company, Bargain price, Great Dividend history. I like my chances.

Recs

0
Member Avatar DuffyRomerica (80.88) Submitted: 9/6/2009 1:55:24 PM : Outperform Start Price: $21.73 BMY Score: +9.90

Passws the Geraldine Weiss criteria as of Sep 6, 2009

Recs

0
Member Avatar RINDER (48.82) Submitted: 9/4/2009 1:58:58 PM : Outperform Start Price: $21.69 BMY Score: +8.85

High dividend yield, Underpriced. Low risk and steady growth

Recs

0
Member Avatar KhelSkie (90.97) Submitted: 8/31/2009 2:57:08 PM : Outperform Start Price: $21.74 BMY Score: +8.96

Drug company that produces everyday items. Enough said.

Recs

0
Member Avatar Momentum21 (66.72) Submitted: 8/24/2009 11:29:01 PM : Outperform Start Price: $22.20 BMY Score: +7.80

Another addition to my pharma collection

Recs

0
Member Avatar PuroDog (89.93) Submitted: 8/22/2009 5:42:04 AM : Outperform Start Price: $22.38 BMY Score: +6.90

Best drugs I ever had

Recs

0
Member Avatar JDKeene (92.68) Submitted: 8/12/2009 1:01:31 PM : Outperform Start Price: $21.65 BMY Score: +8.40

Ford Strong Buy, S&P (4 or 3 stars), Member of S&P 500

Recs

0
Member Avatar sergehandfeld (60.34) Submitted: 8/7/2009 12:29:14 PM : Outperform Start Price: $21.80 BMY Score: +8.44

after all, who doesn't get sick

Recs

0
Member Avatar googs77 (69.81) Submitted: 8/6/2009 1:36:40 PM : Outperform Start Price: $21.46 BMY Score: +7.73

With the purchase of Mederex, BMY has significantly strengthened its cancer treatment pipeline. Stock price is pretty cheap, and is a low risk holding with a nice dividend.

Recs

0
Member Avatar etrader09 (74.62) Submitted: 8/4/2009 9:13:05 PM : Outperform Start Price: $21.67 BMY Score: +7.84

Solid company with bright future, strong R & D. Has more positives than negatives.

Featured Broker Partners